Peak systolic velocity of pulmonary venous flow and mitral annulus are independent predictors of left ventricular global longitudinal strain in patients with cardiomyopathy

Abstract

conduction defect. Am J Cardiol 2006;97:256–9. [3] Abu-Assi E, Otero-Ravina F, Allut Vidal G, et al. on behalf of Grupo Barbanza researchers. AFBAR. Comparison of the reliability andvalidity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol 2011;19:349–54. [4] Garcia-Castelo A, Garcia-Seara J, Otero-Ravina F, et al. Barbanza Group Investigators. Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study). Int J Cardiol 2011;153:68–73. [5] Vidal-Perez R, Otero-Ravina F, Lado-Lopez M, et al. The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study. Int J Cardiol 2013 Oct 3;168(3):2146–52. [6] Okin PM, RomanMJ, Devereux RB, Pickering TG, Borer JS, Kligfield P. Time–voltage QRS area of the 12-lead electrocardiogram: detection of left ventricular hypertrophy. Hypertension 1998;31:937–42. [7] van Dijk Jeroen, Dijkmans Pieter A, Gotte Marco JW, Spreeuwenberg Marieke D, Visser Cees A, Kamp Otto. Evaluation of global left ventricular function and mechanical dyssynchrony inpatientswith anasymptomatic leftbundlebranchblock: a real-time3D echocardiography study. Eur J Echocardiogr 2008;9:40–6. [8] Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23;359:995–1003. [9] Julius S,KjeldsenSE,WeberM,et al. VALUE trial group.Outcomes inhypertensivepatients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;19(363):2022–31.